[CAS NO. 2305045-76-3] XL 188

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2305045-76-3]

Catalog

HY-122886

Brand

MCE

CAS

2305045-76-3

DESCRIPTION [2305045-76-3]

Overview

MDL	-
Molecular Weight	574.71
Molecular Formula	C32H42N6O4
SMILES	O=C(NC1=CC(N=CN2CC3(O)CCN(C(C[C@H](C4=CC=CC=C4)C)=O)CC3)=C(C=C1)C2=O)CCN5CCN(C)CC5

For research use only. We do not sell to patients.

Summary

XL 188 is a potent and selective USP7 inhibitor with IC ₅₀ values of 90 nM and 193 nM for USP7 full-length and catalytic domain enzyme, respectively. XL 188 can be used in research of cancer ^[1] .

In Vitro

XL 188 (1-20 μM; 16 h; MCF7 cells) promotes USP7 dependent loss of HDM2 and increase of p53 and p21 ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis ^[1]

Cell Line:	MCF7 cells
Concentration:	1, 5, 10, and 20μM
Incubation Time:	16 hours
Result:	Had the loss of HDM2 accompanied by an increase in downstream tumor suppressors p21 and p53.

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Stolte B, et, al. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma. J Exp Med. 2018 Aug 6;215(8):2137-2155.